HENDERSON, NV, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. (OTC: BLFE) (the “Company” or “BioLife”), announced today that it has filed Form 1-A with the Securities and Exchange Commission (SEC) seeking to raise up to $20 million under a Tier I Regulation A+ offering.
The filing is structured to raise up to $20 million through the sale of our common stock at a price per share between $.05 and $.50. The final price will be set once the offering statement has been qualified by the SEC. The money raised would be used to fund and expand existing operations, payoff company debt and complete additional acquisitions.
This process and fundraising initiative will also enable BioLife to complete the tasks it requires to become fully SEC reporting and subsequently apply to uplist to the OTCQB tier of OTC Markets, which is also known as The Venture Market.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
Disclaimer
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
This is neither an offer nor a solicitation to sell securities, which may only be done once the Company’s offering on Form 1-A has been qualified by the SEC and in those certain states where the Company seeks to offer its shares.
Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
